Taxanes are the most active drugs in the treatment of metastatic breast and ovarian cancer. Weekly therapy with paclitaxel produces notable activity, with remarkably low toxicity.
Ulrich Canzler, MD
Advertisement
Articles by Ulrich Canzler, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA ODAC Votes No to Camizestrant for HR+/HER2– ESR1 Advanced Breast Cancer
2
FDA ODAC Votes Yes to Capivasertib for PTEN-Deficient Metastatic HSPC
3
Targeting KRAS in Pancreatic Cancer: What is Daraxonrasib’s Mechanism of Action?
4
FDA Grants Priority Review to Tislelizumab/Zanidatamab in 1L HER2+ Gastric Cancers
5